Refractory angina, characterized by chronic chest pain unresponsive to standard medical and revascularization therapies, affects a significant subset of ischemic heart disease patients. The market offers a spectrum of advanced interventions—including novel pharmacological agents (such as ivabradine and ranolazine), gene therapy vectors, cell-based regenerative treatments, enhanced external counterpulsation (EECP), and angiogenic growth factors—that target underlying microvascular dysfunction and promote neovascularization. These products boast advantages like targeted mechanism of action, reduced syste Refractory Angina Treatment Market development is driven by the unmet need for durable symptom relief in patients who cannot undergo further percutaneous coronary intervention or bypass surgery. Moreover, combination regimens integrating pharmacotherapy with device-based EECP expand therapeutic options and enhance patient quality of life. As health systems seek cost‐effective approaches to reduce hospitalizations and improve functional capacity, these cutting-edge treatments gain traction among cardiologists and interventional specialists

According to CoherentMI, The Global Refractory Angina Treatment Market is estimated to be valued at USD 211.3 Mn in 2025 and is expected to reach USD 309.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.

Key Takeaways

Key players operating in the Refractory Angina Treatment Market are

Imbria Pharmaceuticals,

Angionetic Inc, Xylocor Therapeutics Inc,

Caladrius Biosciences Inc.

Imbria Pharmaceuticals has advanced its cell-based regenerative therapy through Phase II trials, while Angionetic Inc leverages proprietary gene delivery platforms to stimulate angiogenesis. Xylocor Therapeutics focuses on metabolic modulators that optimize myocardial oxygen utilization, and Caladrius Biosciences is developing autologous cell therapies aimed at enhancing collateral vessel formation. These companies are strengthening their pipelines through strategic collaborations, licensing agreements, and targeted R&D investments to accelerate regulatory approvals and expand their global footprint.

Get More Insight On: Refractory Angina Treatment Market 

Get this Report in Japanese Language: 難治性狭心症治療市場

Get this Report in Korean Language: 내성협심증치료시장